ADC Therapeutics SA - ADCT STOCK NEWS

ADC Therapeutics has announced the acceptance of pivotal Phase 2 trial results for camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma for an oral presentation at EHA2022 in Vienna, Austria, from June 9-12, 2022. The company expresses optimism regarding Cami’s efficacy and safety as a single-agent therapy, with potential for a Biologics License Application submission. Additionally, data related to ZYNLONTA in diffuse large B-cell lymphoma will be presented in various formats at the congress.

ADC Therapeutics announces a leadership transition as co-founder Chris Martin steps down as CEO, passing the role to Ameet Mallik. Dr. Martin will continue on the Board of Directors and Chair the Science and Technology Committee. Mallik brings extensive experience, having previously served at Novartis and Rafael Holdings. ADC Therapeutics aims to enhance treatment for cancer patients through its targeted antibody drug conjugates (ADCs). The company's current pipeline includes the FDA-approved ZYNLONTA and several promising clinical programs.

ADC Therapeutics reported first-quarter 2022 financial results with net sales of ZYNLONTA at $16.5 million, influenced by inventory build and fewer new patient starts due to the Omicron surge. The company transitioned CEO responsibilities from Chris Martin to Ameet Mallik. Cash and cash equivalents stood at $430.9 million. R&D expenses increased to $49.0 million, while net loss narrowed to $16.7 million from $51.5 million YoY. Key clinical trials and market expansions are underway, with updates anticipated in the coming months.

ADC Therapeutics SA (NYSE: ADCT) announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 1:40 pm ET. The event can be accessed via a live webcast on the company's Investors page, with a replay available for 30 days. ADC Therapeutics focuses on innovative antibody drug conjugates for treating hematologic malignancies and solid tumors, including FDA-approved ZYNLONTA for lymphoma.

ADC Therapeutics (NYSE: ADCT) announced a conference call on May 9, 2022, at 8:30 a.m. ET to discuss its first-quarter financial results and business updates. The call will be accessible via phone and live webcast, with an archived version available for 30 days. The company specializes in targeted antibody drug conjugates for cancer treatment, with its FDA-approved ADC ZYNLONTA (loncastuximab tesirine-lpyl) for diffuse large B-cell lymphoma. ADC Therapeutics is advancing additional clinical trials, including Cami for Hodgkin lymphoma and various solid tumors.

ADC Therapeutics (NYSE: ADCT) announced a permanent J-code, J9359, for ZYNLONTA® effective April 1, 2022. This J-code simplifies the reimbursement process for physicians and improves patient access to treatment. ZYNLONTA, a CD19-directed antibody drug conjugate, is FDA-approved for relapsed or refractory large B-cell lymphoma. The company aims to expand its U.S. presence beyond academic institutions into more community accounts, increasing predictability in reimbursement through the J-code.

ADC Therapeutics, a biotechnology company focused on cancer treatment, announced the filing of its Annual Report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC. The report, detailing comprehensive financial data and performance metrics, is accessible via the SEC website and the company's investor section. ADC's targeted antibody drug conjugates, like ZYNLONTA, which is FDA-approved for treating specific types of lymphoma, signify its commitment to innovative cancer therapies, alongside ongoing clinical developments for other ADCs.

ADC Therapeutics reported ZYNLONTA® net sales of $17.0 million for Q4 2021 and $33.9 million for FY 2021 following its May launch. The LOTIS-5 Phase 3 trial combining ZYNLONTA with rituximab has completed its safety lead-in and is now enrolling randomized participants. The company plans to discontinue the LOTIS-3 trial while focusing on the second-line opportunity for ZYNLONTA. R&D expenses dropped to $42.5 million for Q4, whereas net loss was $34.4 million for the quarter, improving from last year. The company aims to expand ZYNLONTA's availability and advance its clinical pipeline in 2022.

ADC Therapeutics (NYSE: ADCT), a biotechnology firm focused on cancer treatment, announced that CEO Chris Martin will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8 at 2:10 p.m. EST. A live webcast will be available on the company's Investors page.

The company develops next-generation antibody drug conjugates, including the FDA-approved ZYNLONTA® and others in clinical trials.